Signal Transduction and Targeted Therapy (Jun 2022)

CB1R-stabilized NLRP3 inflammasome drives antipsychotics cardiotoxicity

  • Liliang Li,
  • Pan Gao,
  • Xinru Tang,
  • Zheng Liu,
  • Mengying Cao,
  • Ruoyu Luo,
  • Xiaoqing Li,
  • Jing Wang,
  • Xinyi Lin,
  • Chao Peng,
  • Zhihong Li,
  • Jianhua Zhang,
  • Xian Zhang,
  • Zhonglian Cao,
  • Yunzeng Zou,
  • Li Jin

DOI
https://doi.org/10.1038/s41392-022-01018-7
Journal volume & issue
Vol. 7, no. 1
pp. 1 – 15

Abstract

Read online

Abstract Long-term use of antipsychotics is a common cause of myocardial injury and even sudden cardiac deaths that often lead to drug withdrawn or discontinuation. Mechanisms underlying antipsychotics cardiotoxicity remain largely unknown. Herein we performed RNA sequencing and found that NLRP3 inflammasome-mediated pyroptosis contributed predominantly to multiple antipsychotics cardiotoxicity. Pyroptosis-based small-molecule compound screen identified cannabinoid receptor 1 (CB1R) as an upstream regulator of the NLRP3 inflammasome. Mechanistically, antipsychotics competitively bond to the CB1R and led to CB1R translocation to the cytoplasm, where CB1R directly interacted with NLRP3 inflammasome via amino acid residues 177–209, rendering stabilization of the inflammasome. Knockout of Cb1r significantly alleviated antipsychotic-induced cardiomyocyte pyroptosis and cardiotoxicity. Multi-organ-based investigation revealed no additional toxicity of newer CB1R antagonists. In authentic human cases, the expression of CB1R and NLRP3 inflammasome positively correlated with antipsychotics-induced cardiotoxicity. These results suggest that CB1R is a potent regulator of the NLRP3 inflammsome-mediated pyroptosis and small-molecule inhibitors targeting the CB1R/NLRP3 signaling represent attractive approaches to rescue cardiac side effects of antipsychotics.